Innovation at the core.
A small blood test.
A big impact.
This test is a highly specific and sensitive test that can detect, capture and enumerate Circulating Tumor Cells in very low volume of blood. Circulating Tumor Cells are a telltale signature of cancer metastasis.
OncoDiscover® CTC Test empowers oncologists to make better treatment decisions for improved outcomes
See what renowned medical oncologist -Dr Nirmal Raut has to say →
Interpreting the OncoDiscover® CTC Test Report
As cancer cells multiply to form a tumor, they continue to change – becoming more and more different from each other. Hence cancer of one individual is different from that of another, even though the tissue of origin may be same. Circulating Tumor Cells (CTC) number is a personal indicator of a patient's cancer status and must not be used to compare with data of other patients. Circulating Tumor Cells (CTC) are indicative of the real time status of cancer. Based on previous results, it becomes a useful tool to monitor progression. Hence, it is important to do the test on regular intervals to monitor the condition with respect to the initial baseline number.
Circulating Tumor Cells (CTC) are indicative of the real time status of cancer. Based on previous results, it becomes a useful to tool to monitor progression. Hence, it is important to do the test on regular intervals to monitor the condition with respect to the initial baseline number.
*Ref: Qayyumi B, Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;134(1):73-83;
Validation Data*
94.32%
Sensitivity
98%
Specificity
95.17%
Accuracy
Our Numbers
11000+
Tests Performed
10000+
Patients Served
450+
Doctors Trust Us
CTC and Minimal
Residual Disease (MRD)
CTC captured from blood sample of Breast Cancer patient
CTC Cluster captured from blood sample of Mixed Mullerian Cancer patient
Detection of Circulating Tumor Cells (CTC) allows monitoring of minimal residual disease and subsequent metastatic progression. Early therapeutic intervention on the basis of liquid biopsy assessments might improve patient outcomes.
-
The OncoDiscover® Liquid Biopsy Test detects and characterizes minimal residual disease (MRD) by identifying tumor cells shed from the primary lesion.
-
Useful even when there are no clinical or radiological signs of metastasis or residual tumor cells.
-
Enables monitoring of circulating tumor cells (CTCs) during post-treatment follow-up.
-
Allows earlier detection of disease relapse compared to standard radiological imaging.
-
Assesses PD-L1 and Her2 expression on CTCs to guide targeted therapy.
-
Fighting cancer.
One cell at a time.
One in a billion cells.
Even a single tumor cell can cause cancer relapse and can lead to metastasis (spread of cancer). OncoDiscover® CTC Test detects, with pinpoint accuracy, those pesky cells whose presence, even a single one of them, leads to the spread of cancer even after the patient’s treatment has been completed and the patient seems to have recovered.
Cost-effective
The OncoDiscover® CTC Test has been developed with a goal of making it affordable and accessible to everyone who is in need of it. It is 50% cheaper than any other test to diagnose cancer cells.
Time Saving
At OncoDiscover® laboratory the diagnostic test are run on the blood samples of the patients. Typically a complete run cycle is completed within a weeks time followed by analysis by scientific experts.
Accurate
The OncoDiscover® CTC Test can identify pesky tumor cells amongst billions of cells in the blood samples from the patients. It is as accuarate as counting one in a billion cells from the blood sample.
Safe
The OncoDiscover® CTC Test is absolutely safe. Only 5 ml of patients blood sample is collected and subject to the diagnostic runs. Patients don’t need to through any other tests including that involving radiations.
Convenient
The OncoDiscover® CTC Test is a simple blood test. Just book the CTC Test online or through a phone call. Our registered phlebotomists can collect the blood samples from patient’s home.
Pain-free
The patient doesn’t have to go through any medical procedure or go through any tissue biopsy. All that it needs is patients blood samples - ensuring its physically and emotionally pain-free for the patient.
Who should get tested?
High Risk
Factors
Smoking / Chewing Tobacco, Alcohol, Pollution, Work Hazard, Age, and people with family history of cancer.
Individuals with Cancer Symptoms
Unusual bleeding, Change in bowel habits, Unusual lumps, Nagging cough
Individuals taking Cancer Treatment
Chemotherapy, Radiation, Surgery, Hormone Therapy.
Individuals Post Cancer Treatment
To monitor the Chances of cancer relapse
Licences
License No:
MFG / IVD2019 / 000004
License Name:
MD 29 – Permission to import or manufacture new in-vitro diagnostic medical device.
Licensing Authority:
Central Drug Standards Control Organisation (CDSCO), New Delhi, India.
License No:
MFG / IVD2019 / 000031
License Name:
MD 9 – License to Manufacture for Sale or for Distribution of Class C or Class D medical device.
Licensing Authority:
Central Drug Standards Control Organisation (CDSCO), New Delhi, India.
Accreditations
Frequently asked questions
Answers to commonly asked questions about Actorius and our offerings.
The OncoDiscover® Circulating Tumor Cells Test can detect CTCs originating from Epithelial Cancers (Carcinomas). Some major Carcinomas are:
- Head & Neck,
- Breast, Lung,
- Colorectal,
- Prostate,
- Cervical,
- Gall Bladder, etc.These constitute more than 70% of all the Cancers of the world.
However, the OncoDiscover® Circulating Tumor Cells Test does not detect Sarcoma, Melanoma, Lymphoma and Leukemia.
Please contact us to see if you qualify for this test.
-
Patients diagnosed with epithelial cancers: The OncoDiscover® CTC Test can be used to understand the spread of cancer in patients diagnosed with epithelial cancers.
-
Patients undergoing therapy: The OncoDiscover® CTC Test can be used to monitor CTC levels in patients undergoing therapy to understand the effectiveness of the therapy.
-
Patients in remission: The OncoDiscover® CTC Test can be used to monitor CC levels in patients to detect cancer relapse at the earliest stage.
-
Patients with suspected but undetectable epithelial cancers: In many cases, doctors may suspect a cancer due to symptoms or preliminary testing but may not be able to conclusively diagnose a cancer. The OncoDiscover® CTC Test can be used to detect presence of cancer cells in the blood as conclusive evidence of metastasis
-
The OncoDiscover® CTC Test is a simple and safe blood test. In medical terms, it is an in-vitro diagnostic test, which is essentially a test done on samples such as blood taken from human body.
The test requires withdrawing a low volume (5ml) of blood from the patient. The blood will be withdrawn by a trained phlebotomist or a nurse.
We recommend testing once every 3 months to understand the real-time status of the cancer in your body.
For patients currently undergoing therapy, the Oncologist will decide on the timepoint and frequency of testing.
There are no special preparations required for getting tested. You do not need to fast or avoid any food before the test.
There are no special preparations required for getting tested. You do not need to stop any medicine before the blood test.
If no cancer cells were detected by the OncoDiscover® CTC Test, it only means that at present cancer cells are not present in your bloodstream. A cancer cell which may be dormant currently may express itself later. It is essential to continuously monitor the status of cancer.
Only an Oncologist is qualified to decide on the course of action based on the test results. We shall not offer any advice or consultation on cancer therapy.
This test is a real time test of cancer status in the body. This test does not determine the future status of cancer.
Early detection is half the battle won.
Book a Test
Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists.
Sample Collection
Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 5 ml of patient’s blood sample.
Receive Report
A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site.